PATH · UiPath, Inc.

Current Thesis

UiPath's recovery case requires quantified commercial evidence for agent orchestration at the 2026-09-22 Investor Day and a subsequent weekly close above $15; a weekly close below $13.75 would invalidate it. This is a new, low-conviction recovery hypothesis: the August thesis already failed its published $15 weekly-close condition when the shares finished 2026-09-11 at $13.75.

For the August rerating leg, the narrative is dead — the 2026-09-11 close breached its stated price condition despite better company results. The underlying business proposition remains the transition from robotic process automation to coordinating artificial-intelligence agents across enterprise workflows. Investor Day is company-confirmed for 2026-09-22; commercial adoption figures, rather than another product description, are the evidence this recovery hypothesis requires. UiPath's August 25 announcement.

Bullish and bearish views on UiPath, Inc.

The model's bull view on UiPath, Inc. (PATH), in brief: Results cleared the revenue hurdle. For the quarter ended 2026-07-31, UiPath reported revenue of $410 million, up 13% year over year, and operating income under generally accepted accounting principles of $32 million. September 3 results. The recurring business still expanded.… The bear view: Expansion has not established acceleration. Both cases follow in full.

Bull Case

• Results cleared the revenue hurdle. For the quarter ended 2026-07-31, UiPath reported revenue of $410 million, up 13% year over year, and operating income under generally accepted accounting principles of $32 million. September 3 results.
• The recurring business still expanded. Annualized renewal run-rate (ARR) reached $1.938 billion at 2026-07-31, up 12% year over year; net new ARR was $37 million and dollar-based net retention was 109%. September 3 results.
• Management raised the annual outlook. On 2026-09-03, UiPath guided fiscal 2027 revenue to $1.789–1.794 billion and year-end ARR to $2.065–2.070 billion. These replace the lower May ranges in the prior research. Company outlook.

Bear Case

• Expansion has not established acceleration. The $37 million of net new ARR reported on 2026-09-03 was below the $49 million reported on 2026-05-28. This quarterly comparison is insufficient to establish a durable trend. September results; May results cited in the August 30 research.
• Analyst enthusiasm remained divided. Benzinga's 2026-09-04 ratings reports recorded Canaccord's downgrade to Hold with a $17 target, while Mizuho retained Neutral with a $14 target. Citigroup's September 8 initiation carried a $23 target, according to the supplied dated coverage. Those are analyst opinions, not measured commercial outcomes.
• The published structure already broke. The adjusted market close of $13.75 on 2026-09-11 was below the August 30 research's $15 invalidation level. Better financial results did not preserve that price condition.

Setup & Price Structure

The supplied adjusted series records a 2026-09-11 close of $13.75, a three-month price gain of 30.3%, and a price 28.7% below its $19.29 trailing-year high. The 14-period relative strength index was 34.7 on that date. These observations establish substantial remaining medium-term gains alongside recent weakness; they do not establish a base.

The recovery hypothesis uses $13.75 strictly as the September 11 reference close, not as a demonstrated support shelf. Its price objective is a weekly close above the previously published $15 boundary, conditional on commercial evidence at Investor Day. This separate test does not reverse the recorded failure of the August thesis.

Positioning evidence is limited to the September 4 cluster of analyst revisions and the September 8 Citigroup initiation reported in the supplied coverage. No dated fund-flow, short-interest, insider-transaction or moving-average series is available here. Coverage clustering alone cannot establish crowded ownership.

Catalyst Calendar (next 30 days)

• 2026-09-22 — UiPath Investor Day. The company announced a Las Vegas event beginning at 11:30 a.m. Pacific time. The research question is whether management supplies quantified paid adoption or separately identified commercial contribution from agent orchestration; the announcement itself promises no such disclosure. August 25 event announcement.

What Would Change Our Mind

Failure to retain the September 11 reference close would end the recovery hypothesis: a weekly close below $13.75 is its price invalidation. Investor Day passing on 2026-09-22 without quantified paid adoption or identifiable orchestration revenue would separately fail its evidence requirement.

The broken August structure would warrant reassessment only after that commercial disclosure and a subsequent weekly close above $15. Neither condition is established by the September 11 price record or the August 25 event announcement.

Correlation Notes

This remains a single-name recovery hypothesis. The August 30 research attributed the August 27 advance to Salesforce's August 26 results, while the September 4 Benzinga coverage places UiPath's decline alongside its own earnings reaction. Those observations do not provide enough paired returns to estimate correlation or separate software-sector exposure from company-specific repricing. The sample is too small to support a correlation claim.